Introduction
Unexpected readmission and mortality after intensive care unit (ICU) discharge is a potentially preventable adverse outcome after apparent successful treatment of critical illness. Despite significant improvement in overall outcomes of critically ill patients in the past two decades, post-ICU readmission and mortality rates remain high and exceed 4% in many institutions. [1] Post-ICU readmission and mortality are intrinsically interrelated, with a four-fold increase in hospital mortality for patients who are readmitted. [2] [3] [4] [5] [6] These two adverse outcomes after ICU discharge also share similar risk factors, with patients with chronic health conditions and unstable physiological parameters at ICU discharge being most vulnerable to these adverse events after ICU discharge. [7] [8] Although some prognostic scores have been shown to predict post-ICU readmission and mortality [9] [10] , many of these scores are difficult to estimate at the bedside, and as such, most practising clinicians still rely on subjective assessment of their patients to determine whether their patients are suitable for ICU discharge. [11] Recurrent or persistent infection and inflammation may play a role in leading to unexpected readmission or mortality after ICU discharge. This hypothesis is supported by the fact that inflammatory markers such as C-reactive protein (CRP) and white blood cell count at ICU discharge were more likely to be elevated among those who were subsequently readmitted compared to those without readmission. [11] [12] [13] [14] [15] Similarly, eosinopenia, a marker of bacterial infection, at ICU discharge had also been reported to be more common among those who experienced post-ICU readmission or mortality compared to those without such adverse events. [16] Procalcitonin (PCT) has a shorter half-life and is more specific in its association with infection than CRP. [17] [18] Indeed, normalization of PCT has A C C E P T E D M A N U S C R I P T
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been suggested to be useful in guiding when cessation of antibiotic for patients with infection. [19] [20] [21] Recently, a high PCT concentration at ICU discharge was also reported to be associated with an increased risk of unexpected mortality after ICU discharge in a small cohort study. [22] We hypothesized that an elevated PCT concentration at ICU discharge is a reliable predictor for adverse outcomes after ICU discharge, and conducted a cohort study to assess whether PCT concentration at ICU discharge is a better predictor for post-ICU readmission and mortality than CRP concentrations and eosinopenia.
Specifically, we assessed whether measuring these inflammatory markers at ICU discharge was more predictive of post-ICU readmission or mortality in patients admitted to the ICU with an infective cause.
Materials and methods
This was a single-centred retrospective cohort study. After obtaining approval from the Fremantle Hospital Quality and Safety Unit approval, outcome and laboratory data of all patients who were admitted to the ICU between April 1, 2012 and March 31, 2014 were retrieved for this study. Fremantle hospital ICU was a 12-bed multidisciplinary ICU admitting patients from all medical specialties and most surgical specialties, including cardiothoracic surgery. Patients after organ transplantation, multiple trauma, neurosurgery and burns were not admitted to this ICU. This ICU had a policy of measuring daily PCT concentrations for all patients.
PCT was measured by BRAHMS PCT ECLIA®; Roche Diagnostics, Switzerland, with a normal range <0.05ug/ml. CRP was measured in mg/ml (normal range: <1mg/ml). During the study period, patients were discharged from the ICU once the patients did not require any organ support and were deemed to be safe to be or were discharged with a plan to limit life support were excluded from this study. For patients who were readmitted to the ICU during the same hospitalization, only the data of their first ICU admission were considered. None of the patients were lost to follow-up or had missing mortality data.
Statistical analysis
Continuous and discrete data were presented in median with interquartile range (IQR) and count with percentage, respectively. Differences in continuous outcomes with skewed distributions and categorical outcomes were analyzed by
Mann-Whitney and Chi Square tests, respectively. Area under the receiveroperating-characteristic (ROC) curve was used to determine the ability of different predictors in discriminating patients with and without adverse events after ICU discharge. As some of these biomarkers may not have a linear association with the risk of adverse post-ICU events, [23] the predictive ability of the biomarkers was further assessed by analysing them as a categorical variable using the cut-off values previously reported to be useful. [12] [13] [14] 16] In this study, areas under the ROC curve (Figure 1) . The median number of days for readmission and hospital mortality after first ICU discharge were 4 (IQR 2-9) and 18 (IQR 7-45), respectively.
In the univariate analyses, severity of acute illness on first presentation to ICU, non-elective admission, infection as a cause for admission, chronic renal disease (9% vs. 3%), PCT concentrations at ICU discharge (0.6 vs. 0.4ug/L, p=0.002) and a high C-reactive protein (CRP) concentration (>100mg/L)(58% vs.
41%, p=0.004) were associated with an increased risk of post-ICU readmission or mortality ( Table 1) .
As a continuous predictor, none of the inflammatory markers including PCT and CRP concentrations at ICU discharge could be considered satisfactory in
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discriminating between patients with and without post-ICU readmission or mortality ( p=0.008) were significantly associated with an increased risk of post-ICU readmission or mortality (Table 3) , and this association did not appear to be different between patients admitted to ICU with an infection and those admitted with noninfective causes (Figure 2) .
Discussion
This study showed that as a continuous predictor, none of the inflammatory markers at ICU discharge, including PCT concentrations, had enough discrimination to be useful in predicting post-ICU readmission or mortality. As a dichotomized variable, CRP>100mg/L at ICU discharge was associated with about twice the risk of post-ICU readmission or mortality of those with CRP<100mg/L, for both patients admitted to ICU due to infective and non-infective causes. These findings have some clinical significance and require further consideration.
First, despite PCT is more specifically associated with infection than CRP or WBC count, we could not demonstrate its prognostic significance in predicting readmission or mortality after ICU discharge for both patients admitted to ICU with infection and other diagnoses. Although PCT concentrations were statistically different between those who were readmitted or died after ICU discharge and those without such adverse events, the difference was not clinically important nor was its area under the ROC curve. This negative finding may be due to the fact that not all ICU readmissions or post-ICU deaths are caused by infection. Indeed, we only had culture-confirmed infection as a cause for readmission in 9% of the ICU
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readmissions, and comorbidities such as chronic renal failure could account for some of the adverse events after ICU discharge. Furthermore, because the half-life of PCT is short, it may not be useful to predict infection that occurs some days later, as in our patients when the median time for ICU readmission was 4 days.
Second, some previous studies have shown that CRP at ICU discharge may be useful in predicting both readmission and unexpected mortality after ICU discharge. [11] [12] [13] [14] [15] CRP concentrations at ICU discharge in our patients were not as useful in predicting adverse events as previously reported. This may be explained by a large proportion of elective admissions (42%) with a lower acuity illness compared to previous studies. Nevertheless, a substantially elevated CRP concentration (>100mg/L) at ICU discharge may still be useful, as an adjunct to other clinical assessments, in determining whether the patient is suitable for ICU discharge. The association between a high CRP concentration at ICU discharge and post-ICU readmission or mortality did not appear to be too different among those admitted to ICU with infection or non-infective cause (Figure 2) , suggesting that persistent inflammation without infection may still be associated with poor patient outcomes after ICU discharge.
The ability of PCT to distinguish between sepsis and inflammation, as well as types of sepsis, has recently been challenged. PCT levels seem to be much higher in gram negative sepsis compared to gram positive sepsis and may be higher in bacterial infections rather than non-bacterial infections. [24] A recent study looking at PCT concentrations in acute liver failure patients also found poor correlation between sepsis and PCT levels in this type of patients, presumably due to presence of extensive inflammation. [25] Regardless, our study attempted to study all ICU patients rather than a specific cohort.
There are strengths and limitations in this study. As far as we know, this is the largest cohort study examining the prognostic value of PCT at ICU discharge for patients admitted to ICU with and without infection. We also did not have missing mortality data in our patients and have excluded patients who were deemed to be not suitable for further life-support treatment or ICU readmission. This is, however, a single-centre study and our results may not be generalizable to centres that have different case-mix, as well as readmission and post-ICU mortality rates. Finally, using PCT and CRP as a guide to confirm resolution of infection with antibiotics has been proposed before this study was initiated. Because this was not a blinded study, it is possible that some ICU discharge decisions for our patients had been affected by the results of the inflammatory markers, potentially reducing their prognostic significance.
In conclusion, after excluding patients who had limitation of life-support order, a high CRP concentration (>100mg/L) at ICU discharge was associated with an increased risk of unplanned ICU readmission or post-ICU mortality, in both patients initially admitted to ICU with infection and non-infective causes. As a continuous or dichotomized variable, PCT concentration at ICU discharge was inadequate in its predictive ability to guide ICU discharge. More research is needed to assess whether other biomarkers are more useful than CRP and PCT in predicting adverse outcomes after ICU discharge. Table 2 . Area under the receiver-operating-characteristic (ROC) curve for different inflammatory markers at ICU discharge in discriminating between patients with and without post-ICU readmission or mortality. 
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